TransTech Pharma Acquires Three Programs for the Treatment of Metabolic Disorder from Novo Nordisk

TransTech Pharma, Inc. and Novo Nordisk A/S have announced that TransTech has acquired all rights from Novo Nordisk to a portfolio of drug candidates being developed to treat metabolic disorders. This portfolio is comprised of three distinct therapeutic approaches to such treatment: H3 receptor antagonists, PPARd agonists, and 11ßHSD1 inhibitors.

After determining in January 2007 to focus all Novo Nordisk research and development resources on the company's growing pipeline of protein-based pharmaceuticals, the company divested all existing preclinical and clinical small-molecule projects.

Novo Nordisk selected TransTech to develop these three programs based on its prior success working closely with TransTech on novel drug development.

"We are very pleased to place our programs in such good hands. We have previously partnered with TransTech, and know that TransTech has the capability to effectively and expeditiously proceed with the further development of these programs," said Novo Nordisk Executive Vice President and Chief Scientific Officer Mads Krogsgaard Thomsen.

"This allows us to focus our R&D efforts on therapeutic proteins while keeping a financial stake in the programs as a TransTech shareholder."

"We are extremely pleased to have prevailed in the acquisition process and to add these programs to our robust diabetes and obesity portfolio," said Adnan Mjalli, PhD, TransTech's founder, chairman and chief executive officer.

"We are confident that all three programs represent promising approaches to addressing unmet medical needs. These additions to the pipeline will allow TransTech to become a world leader in the discovery and development of novel treatments for diabetes, obesity and other metabolic disorders."

TransTech's current diabetes and obesity portfolio includes orally administered and novel therapeutic development candidates targeting PTP1b inhibitors, AgRP inhibitors, GLP1R agonists, AMPK activators and glucokinase activators.

Now, with the addition of the three Novo Nordisk programs, TransTech is engaged in 11 clinical and preclinical programs in this area. Despite the enormous investment in the discovery of new therapeutics for metabolic disorders, more than 84 percent of all diabetics have an uncontrolled disease and one in three Americans born in 2000 are expected to develop the disease and experience its range of harmful symptoms and side effects.

"TransTech Pharma is in a unique position to potentially treat metabolic disorders through novel, multifaceted therapeutic approaches that address obesity, hepatic glucose output, insulin resistance, beta cell preservation, dyslipidemia and microvascular complications," Dr. Mjalli said.

TransTech made an undisclosed one-time payment to Novo Nordisk for acquisition of the programs.